TORONTO, ON--(Marketwired - August 11, 2016) -


PharmaCan Capital Corp. (TSX VENTURE: MJN) ("PharmaCan" or the "Company") is pleased to announce the closing of the first tranche (the "First Tranche") of the previously announced non-brokered private placement of up to 42,857,143 common shares at a price of CAD$0.35 per share for total gross proceeds of up to CAD$15,000,000 (the "Offering"). The First Tranche closed today and resulted in the issuance by the Company of 18,743,352 common shares at a price of CAD$0.35 per share for total gross proceeds of approximately CAD$6,560,173. No Insiders (as defined in TSX-V Policy 1.1) subscribed for shares in this First Tranche. The proceeds of the Offering will be used for the financing by the Company of its acquisition of Peace Naturals Project Inc.

All securities issued in connection with the Offering are subject to a regulatory hold period of four months and a day in accordance with the rules and policies of the TSX Venture Exchange and applicable Canadian securities laws, and such further restrictions as may apply under foreign securities laws. Completion of the financing is subject to final approval of the TSX Venture Exchange.

About PharmaCan Capital Corp.

PharmaCan Capital Corp. is a holding company for Licensed Producers under Canada's Marihuana for Medical Purposes Regulations (MMPR). With interests in five Licensed producers and three license applicants, PharmaCan is focused on building iconic brands providing patients with compassionate, personalized care.

Forward Looking Statements

This news release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements about strategic plans, including the Company's ability to implement its business development strategy. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements and the forward-looking statements are not guarantees of future performance. All forward-looking information contained in this news release is given as of the date hereof and is based upon the opinions and estimates of management and information available to management as at the date hereof. Except as required by law, PharmaCan disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. Readers are cautioned not to put undue reliance on these forward-looking statements. This news release contains information obtained by the Company from third parties, including but not limited to market data. The Company believes such information to be accurate but has not independently verified such information. To the extent such information was obtained from third party sources, there is a risk that the assumptions made and conclusions drawn by the Company based on such representations are not accurate.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:

Investor & Media Relations
Michael Krestell
PharmaCan Capital Corp.
Phone: (416) 603-7381 EXT #236